Discover
LRMR
Larimar Therapeutics, Inc.
4.31
20 x 4.01
6 x 4.40
bid
ask
+
0.30
7.48%
12764 @ 04:00 PM
4.31 +0.00 (0.00%)
| Ytd | 13.12% | |
| 1y | 14.02% |
4.02
day range
4.38
2.71
52 week range
6.42
| Open | 4.10 | Prev Close | 4.01 | Low | 4.02 | High | 4.38 | Mkt Cap | 447.74M |
| Vol | 0.00 | Avg Vol | 2.11M | EPS | -1.95 | P/E | -2.21 | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.65 | 200-d Avg | 3.90 | 1yr Est | 20.41 |
| Income Statement | |||
| Operating Expenses | 34.35M | ||
| Research and Development Expense | 28.00M | ||
| Selling, General and Administrative Expense | 6.35M | ||
| Operating Income | -34.35M | ||
| Net Income | -32.78M | ||
| Net Income Common Stock | -32.78M | ||
| Net Income Common Stock (USD) | -32.78M | ||
| Consolidated Income | -32.78M | ||
| Earnings per Basic Share | 0.30 | ||
| Earnings per Basic Share (USD) | 0.30 | ||
| Earnings per Diluted Share | 0.30 | ||
| Earning Before Interest & Taxes (EBIT) | -32.78M | ||
| Earning Before Interest & Taxes (USD) | -32.78M | ||
| Weighted Average Shares | 103.88M | ||
| Weighted Average Shares Diluted | 103.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 93.14M | ||
| Cash and Equivalents (USD) | 93.14M | ||
| Investments | 63.58M | ||
| Investments Current | 63.58M | ||
| Current Assets | 160.67M | ||
| Property, Plant & Equipment Net | 3.69M | ||
| Total Assets | 165.30M | ||
| Debt Current | 1.20M | ||
| Total Debt | 4.96M | ||
| Current Liabilities | 34.17M | ||
| Debt Non-Current | 3.75M | ||
| Total Liabilities | 37.92M | ||
| Accumulated Retained Earnings (Deficit) | -497.23M | ||
| Accumulated Other Comprehensive Income | -12.00K | ||
| Shareholders Equity | 127.38M | ||
| Shareholders Equity (USD) | 127.38M | ||
| Assets Non-Current | 4.63M | ||
| Total Debt (USD) | 4.96M | ||
| Liabilities Non-Current | 3.75M | ||
| Trade and Non-Trade Payables | 7.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 50.00K | ||
| Net Cash Flow from Financing | -435.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -85.38M | ||
| Capital Expenditure | -130.00K | ||
| Issuance (Purchase) of Equity Shares | -435.00K | ||
| Net Cash Flow from Investing | -40.91M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -40.78M | ||
| Net Cash Flow from Operations | -44.03M | ||
| Share Based Compensation | 2.15M | ||